ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Wall Street analysts forecast ABUS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABUS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Arbutus Biopharma Corp revenue for the last quarter amounts to 529.00K USD, decreased -60.49 % YoY.

Arbutus Biopharma Corp. EPS for the last quarter amounts to -0.04 USD, decreased -60.00 % YoY.

Arbutus Biopharma Corp (ABUS) has 44 emplpoyees as of December 18 2025.

Today ABUS has the market capitalization of 892.38M USD.